Impact of postoperative duration of Aspirin use on longevity of bioprosthetic pulmonary valve in patients who underwent congenital heart disease repair Tae 
Introduction
Current bioprosthetic valves have excellent hemodynamic performance and remain free from structural deterioration for up to 15 years 1) . But, bioprosthetic valves are heterografts made primarily of porcine or bovine tissue, each with comparable risks of thromboem bolism 2) . Prophylaxis for thromboembolism should be based on pathogenesis and risk. The peak incidence occurs during the first 3 months after valve surgery, probably reflecting the lack of endothelialization of the newly implanted prosthetic and biologic material 35) . We usually use an aspirin for protection of thrombogenic phenomenon after pulmonary valve replacement (PVR) using bioprosthetic valve. However, evidence that long duration aspirin use is appropriate is currently lacking. Therefore, we aimed to analyze the impact of Korean J Pediatr 2016;59 (11) : [446] [447] [448] [449] [450] postoperative duration of aspirin use on longevity of biopro sthetic pulmonary valve in patients who underwent congenital heart disease repair.
Materials and methods
We retrospectively reviewed the clinical data of 137 patients who underwent PVR using bioprosthetic pulmonary valve in Sejong Cardiovascular Institute from January 2000 to December 2003. The patients' data before 2000 years are inaccurate in Sejong General Hospital. And the purpose of this retrospective study is to analyze the longevity of bioprosthetic pulmonary valve at about 10 years after PVR. Therefore, we established the period from January 2000 to December 2003. Among them, 42 were followup loss. And, 6 who underwent early rePVR due to infec tive endocarditis and peripheral pulmonary artery stenosis were excluded. As a result, 89 patients were included in our study and classified as group I (≤12 months) and group II (>12 months) according to duration of aspirin use. We analyzed the echocardio graphic data for the amount of pulmonary valve stenosis and regurgitation from 9 to 11 years postPVR. The amount of pulmo nary valve stenosis was classified as mild (<30 mmHg), moderate (30-50 mmHg), and severe (>50 mmHg) by peak pressure gradient. The amount of pulmonary valve regurgitation was classified as mild, moderate, and severe by examiner's description. In addition, we analyzed the rate of early rePVR due to biopros thetic pulmonary valve failure below 10 years. Additionally, we analyzed for patients who used Hancock II and were under 13 years old. The most common type of bioprosthetic valve to be used during PVR is Hancock II in our patients. And it would be more accurate to compare the same valve, so we performed sub group analysis for patients who used Hancock II. Furthermore, since the young patients (under 13 years old) have different calcium metabolism and immune mechanism from adults, we analyzed patients under 13 years old. The Institutional Review Board of Sejong General Hospital approved this retrospective study.
Results
Totally 89 patients were analyzed of which, 53 were male and 36 were female. Their mean age at the time of PVR was 14.3±8.9 years old (range, 2.6-48 years) and mean body weight was 37.6± 14.7 kg (range, 14-72 kg). Their congenital heart diseases consisted of tetralogy of Fallot 48, pulmonary atresia with ven tricular septal defect 22, fallot type double outlet right ventricle 6, pulmonary atresia with intact ventricular septum 4 Values are presented as mean±standard deviation or number. Group I, the patients who used aspirin less than 12 months (≤12 months); group II, the patients who used aspirin more than 12 months (>12 months); ASA, acetylsalicylic acid (aspirin); PVR, pulmonary valve replacement.
We analyzed echocardiographic data from 10year postPVR. The mean followup duration of echocardiography was 9.85±0.52 years in group I and 9.81±1.90 years in group II (P=0.920). In analysis of the amount of pulmonary stenosis, group I had 16 mild, 8 moderate, and 4 severe patients; and group II had 20 mild, 9 moderate, and 5 severe patients (P=0.945). In pulmonary regur gitation, group I had 23 trivial and mild, and 5 moderate pa tients; and group II had 30 trivial and mild, and 4 moderate pa tients (P= 0.901). Analysis of followup echocardiographic data indi cated no statistical difference between groups (Table 3 ). The 10year re PVR free rate was 70 to 80 percent. Overall freedom from rePVR at 10 years showed no significant difference (P=0.597) (Fig. 1) ; and thromboembolic event was absent in all patients.
Additionally, we analyzed 60 patients who were corrected by Hancock II valve and they were classified as group I (n=27) and group II (n=33). In comparison of aspirin use duration, Group I was 7.4±2.6 months and group II is 32.8±28.2 months (P=0.000). However, there was no difference in gender ratio (P=0.875), mean age at PVR (P=0.267), mean body weight at PVR (P=0.537), and numbers of early rePVR (P=0.481) between both groups (Table 4) . The mean followup duration of echocardiography was 9.95±0.52 years in group I and 9.70±2.20 years in group II (P=0.558). In comparison of pulmonary stenosis, most patients had mild degree pulmonary stenosis and there were no significant difference in both groups (P=0.789). Also, in comparison of pulmonary regur gitation, there was no difference between groups (P=0.782) ( Table  5 ). Overall freedom from rePVR at 10 years showed no signifi cant difference (P=0.484) (Fig. 2A) .
Finally, we analyzed 49 patients under 13 years old because of the reason that we mentioned above. They were classified as group I (n=22) and group II (n=27). The mean duration of aspirin use in group I was 7.1±2.9 and group II was 31.5±26.3 months (P=0.000). However, there was no difference in gender ratio (P= 0.494), mean age at PVR (P=0.522), mean body weight at PVR (P=0.995), and numbers of early redo PVR (P=0.778) between both groups (Table 6 ). Overall freedom from rePVR at 10 years showed no significant difference (P=0.604) (Fig. 2B) . Values are presented as mean±standard deviation or number. Group I, the patients who used aspirin less than 12 months (≤12 months); group II, the patients who used aspirin more than 12 months (>12 months).
Time (yr)
Freedom from re-PVT Overall freedom rate from re-PVR after PVR. The overall freedom rate from re-PVR at 10 years shows no significant difference between group I (≤12 months) and group II (>12 months) according to duration of aspirin use (P=0.597). PVR, pulmonary valve replacement. Values are presented as mean±standard deviation or number. Group I, the patients who used aspirin less than 12 months (≤12 months); group II, the patients who used aspirin more than 12 months (>12 months).
Korean J Pediatr 2016;59(11):446-450 mg to 100 mg per day is rea sonable in all patients with a bio prosthetic aortic or mitral valve for long term 8) . Also, the guide line is described as follows in European Society of Cardiology/ European Association for CardioThoracic Surgery Guidelines (version 2012). Oral anticoagulation may be considered for the first 3 months after implantation of an aortic and mitral biopro sthesis. Lowdose aspirin should be con sidered for the first 3 months after implantation of an aortic and mitral bioprosthesis 9) . The American College of Chest Physicians' guidelines recommend aspirin over warfarin (except for patients with atrial fibrillation) 10) . These guidelines were developed in an attempt to minimize the risk of thromboembolism during the highrisk period.
On the other hand, the guidelines for the use of warfarin and aspirin after bioprosthetic PVR remain under discussion. The risk of thromboembolic complications after bioprosthetic replacement of the pulmonary valve appears to be low, and the risk of sys temic embolization is essentially nonexistent 7) . However, patients usually use aspirin because of the potential to adversely affect the availability and durability of valve. Therefore, in our hospital, some patients were taking aspirin within 1year postPVR and some patients for more than 1year postPVR according to the cardiologist's preference. Because the duration of complete endo thelialization of bioprosthetic valve in pulmonary valve might be from 3 to 6 months, we decided to 1 year as criteria for duration of aspirin use. When patients are classified according to 12 months, we expected that the mean duration of aspirin use in short duration group would be about 6 months. Actually, the mean duration of aspirin use in short duration group was 7.3 months and it was almost same with our expectation.
Generally, our indication for PVR was as follows. In patient
Discussion
Patients with prosthetic valves are at increased risk for both valve thrombosis and arterial thromboembolic events 6) . Conse quently, the anticoagulation therapy is used to lessen the throm boembolic risk. Despite anticoagulation, patients remain at risk for thromboembolic complications, and anticoagulation therapy has the additional risk of bleeding. The risk of thromboembolic and bleeding complications is present even in patients with optimal anticoagulation and is influenced by patient factors and valve position 7) . The optimal initial antithrombotic treatment remains an important unresolved issue in patients undergoing bioprosthetic PVR.
The 2014 American Heart Association/American College of Cardiology guidelines clearly recommend the use of an antico agulation regimen for the first 3 months after biopro sthetic aortic valve replacement and mitral valve replacement in patients to achieve an international nor malized ratio of 2.5 and aspirin 75 . The above results suggest that taking aspirin for more than 1 year postPVR does not affect the valve function. The appro priate duration of aspirin use for optimal valve function remains un clear and may be shorter than 6 months. Importantly, the results of our study indicated that taking aspirin for more than about 7month postPVR is not needed, providing the rationale to alle viate the burden of longterm aspirin use in patients who undergo bioprosthetic PVR.
In most studies that analysed the outcomes of PVR in young patients, younger age and smaller valve size were believed to be the important risk factors for early reoperation for PVR 12, 13) . A calcification of tissue valves is strongly associated with active calcium turnover by growth 14) and the immunological response of patients to xenoantigens 15, 16) , especially in young patients. In addition, it is clear that a small prosthetic valve in pediatric pa tients shows relative stenosis over time. Therefore, we analyzed young patients group under 13 years old and there was no signi ficant difference in longevity of bioprosthetic pulmonary valve.
Our study had several limitations of retrospective review, small number, not small followup loss, and heterogeneity of disease entity and bioprosthetic valve. And, although many factors can influence the progression of pulmonary stenosis, but we analyzed the longevity of bioprosthetic pulmonary valve which was classi fied only according to the duration of aspirin use. Therefore, it could be the limitation to assume that all other factors are on the same condition. In conclusion, longterm aspirin use above 7 months in patients who underwent PVR with bioprosthetic valve showed no benefit. Therefore, we recommend aspirin only short duration for patients with postbioprosthetic PVR. Actually, the pa tients who underwent PVR are taking aspirin for 6 months in our hospital as the result. Further prospective investigation is required to evaluate outcomes for aspirin use of less than 6 months.
